Current Report Filing (8-k)
13 12월 2017 - 6:53AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date
of Earliest event Reported): December 6, 2017
TARGETED
MEDICAL PHARMA, INC.
(Exact name
of registrant as specified in its charter)
DELAWARE
|
|
000-53071
|
|
20-5863618
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2980 BEVERLY GLEN CIRCLE, SUITE 100
LOS ANGELES, CA 90077
(Address
of principal executive offices)
(310) 474-9808
(Registrant’s
telephone number, including area code)
Not Applicable
(Former name
or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below):
¨
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 6, 2017, Mr. Kim Giffoni tendered his
resignation as Interim Chief Executive Officer of Targeted Medical Pharma, Inc. (the
“Company”
) to
focus on other business activities. At the time of his resignation, Mr. Giffoni served as Interim Chief Executive Officer and
Director. Mr. Giffoni will remain a member of the Company’s Board and will serve as the Company’s Executive Vice
President of Foreign Sales. Mr. Giffoni did not resign as a result of any disagreement with the Company on any matter
relating to the Company’s operations, policies or practices. Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).Emerging growth company ¨If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
An interim Chief Executive Officer, Marcus Charuvastra, the
Company’s former VP of Operations and Marketing and a current Director has been appointed by the board.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 12, 2017
|
TARGETED MEDICAL PHARMA, INC.
|
|
|
|
|
|
|
|
By: /s/
|
Marcus Charuvastra
|
|
|
Name: Marcus Charuvastra
|
|
|
Interim Chief Executive Officer
|
Targeted Medical Pharma (CE) (USOTC:TRGM)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Targeted Medical Pharma (CE) (USOTC:TRGM)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024
Targeted Medical Pharma Inc (CE) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Targeted Medical Pharma, Inc. News Articles